Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever?

被引:0
|
作者
Erden, A. [1 ]
Batu, E. D. [2 ]
Sari, A. [1 ]
Sonmez, H. E. [2 ]
Armagan, B. [1 ]
Demir, S. [2 ]
Firat, E. [3 ]
Bilginer, Y. [2 ]
Bilgen, S. A. [1 ]
Karadag, O. [1 ]
Kalyoncu, U. [1 ]
Kiraz, S. [1 ]
Ertenli, I. [1 ]
Ozen, S. [2 ]
Akdogan, A. [1 ]
机构
[1] Hacettepe Univ, Div Rheumatol, Dept Internal Med, Fac Med, Ankara, Turkey
[2] Hacettepe Univ, Div Rheumatol, Dept Paediat, Fac Med, TR-06100 Ankara, Turkey
[3] Hacettepe Univ, Dept Internal Med, Fac Med, Ankara, Turkey
关键词
familial Mediterranean fever; colchicine resistance; colchicine unresponsiveness; RECOMMENDATIONS; ASSOCIATION; MANAGEMENT; DIAGNOSIS; ANAKINRA; CRITERIA; CHILDREN; SCORE; FMF;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Colchicine is the main therapy for familial Mediterranean fever (FMF); however, 5-10% of patients are colchicine-resistant. There is no standard and validated definition for colchicine resistance. We aimed to compare the existing definitions for colchicine resistance in both adult and paediatric FMF patients to find out the best definition to determine colchicine-resistant patients. Methods. 385 FMF patients were evaluated and patients receiving antiinterleukin-1 treatment were included. The anti-IL-1 therapy had been initiated by the experts in the past based on their experience. Eleven different definitions (found out after PubMed search for colchicine resistance in FMF) were applied to all patients. Results were re-analysed after excluding the patients who had no clinical attacks but persistently high acute phase reactants (APRs) and/or amyloidosis. Results. Sixty patients (40 adults/20 children) who had been using anti-IL-1 therapy were included into this study as colchicine-resistant patients. The highest percentage of patients fulfilled definition 5 (93.3%). Definition 9 had the poorest performance (26%). Significantly, a higher percentage of adult patients met definitions 4 and 6 than paediatric patients (87.5% vs. 50%, p= O. O02; 75% vs. 40%, p= O. O08, respectively). After excluding patients without clinical attacks, the highest percentage of patients fulfilled definition 2 (94.4%). We combined the attack frequency (> 1 typical episode/3 months) in definition 2 and presence of amyloidosis/APR increase (increase in ! 2/3 APRs) in definition 5 to create a new definition which was met by 59 (98.3%) colchicine-resistantF MF patients. Conclusion. Definition of colchicine resistance is still controversial. Definitions with both clinical and laboratory criteria were met by a higher percentage of resistant patients than those without laboratory criteria. However, the proper definitions for the attack-free period and persistence of APRs are still lacking.
引用
收藏
页码:S97 / S102
页数:6
相关论文
共 50 条
  • [31] Colonoscopic, genetic and laboratory characteristics of Colchicine-resistant Familial Mediterranean Fever
    Tumgor, Gokhan
    Agin, Mehmet
    Ozhan, Aylin Kont
    Yilmaz, Mustafa
    Karakoc, Gulbin Bingol
    Altintas, Derya Ufuk
    KUWAIT MEDICAL JOURNAL, 2020, 52 (04): : 375 - 380
  • [32] Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review
    Akarcan, Sanem Eren
    Dogantan, Seyda
    Karaca, Neslihan Edeer
    Aksu, Guzide
    Kutukculer, Necil
    RHEUMATOLOGY INTERNATIONAL, 2020, 40 (01) : 161 - 168
  • [33] Do all colchicine preparations have the same effectiveness in patients with familial Mediterranean fever?
    Baglan, Esra
    Ozdel, Semanur
    Bulbul, Mehmet
    MODERN RHEUMATOLOGY, 2021, 31 (02) : 481 - 484
  • [34] Safety and efficacy of intravenous Colchicine in children with Familial Mediterranean Fever
    Tal, Rotem
    Oz, Rotem Semo
    Amarilyo, Gil
    Eidlitz-Marcus, Tal
    Goldberg, Ori
    Levinsky, Yoel
    Peled, Orit
    Harel, Liora
    RHEUMATOLOGY INTERNATIONAL, 2020, 40 (01) : 121 - 128
  • [35] Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases
    Cakan, Mustafa
    Karadag, Serife Gul
    Ayaz, Nuray Aktay
    TURKISH JOURNAL OF PEDIATRICS, 2020, 62 (02) : 167 - 174
  • [36] Anakinra for colchicine refractory familial Mediterranean fever: a cohort of 44 patients
    Marko, Limor
    Shemer, Asaf
    Lidar, Merav
    Grossman, Chagai
    Druyan, Amit
    Livneh, Avi
    Kivity, Shaye
    RHEUMATOLOGY, 2021, 60 (06) : 2878 - 2883
  • [37] Emergence of colchicine resistance in pediatric familial Mediterranean fever: A harbinger of severe enterocolitis
    Stephenson, Aidan Michael
    Chow, Jacky
    Seth, Sanjay
    Miettunen, Paivi
    CRITICAL PUBLIC HEALTH, 2024, 34 (01) : 132 - 133
  • [38] The feasibility of withdrawing canakinumab in paediatric colchicine-resistant familial Mediterranean fever patients
    Sozeri, B.
    Sonmez, H. E.
    Karadag, S. G.
    Baglan, E.
    Ozturk, K.
    Cakan, M.
    Demir, F.
    Yener, G. Otar
    Ozdel, S.
    Ayaz, N. Aktay
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (05) : S118 - S123
  • [39] Efficacy and safety of anti-interleukin-1 in children with colchicine-resistant familial Mediterranean fever
    Erkilet, Hatice Kubra
    Yildirim, Deniz Gezgin
    Esmeray, Pelin
    Soylemezoglu, Oguz
    PEDIATRICS INTERNATIONAL, 2023, 65 (01)
  • [40] Adherence to best practice consensus guidelines for familial Mediterranean fever: a modified Delphi study among paediatric rheumatologists in Turkey
    Kayaalp, Gulsah Kavrul
    Sozeri, Betul
    Sonmez, Hafize Emine
    Demir, Ferhat
    Cakan, Mustafa
    Ozturk, Kubra
    Karadag, Serife Gul
    Yener, Gulcin Otar
    Ozdel, Semanur
    Baglan, Esra
    Celikel, Elif
    Sahin, Nihal
    Yildirim, Deniz Gezgin
    Omeroglu, Rukiye Eker
    Ayaz, Nuray Aktay
    RHEUMATOLOGY INTERNATIONAL, 2022, 42 (01) : 87 - 94